This phase II trial tests how well botensilimab and balstilimab versus nivolumab and ipilimumab works to treat patients with clear cell renal cell carcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced).

Cabozantinib and sunitinib are both FDA approved and commercially available for the treatment of advanced kidney cancer, including vhRCC.

RCC is a cancer that is poorly understood. The increase in both incidence and mortality rates for RCC, coupled with the lack of effective therapies for RCC beyond surgical excision, underscore the need for a better understanding of RCC tumor biology, immunology, and epidemiology.

NCI supports clinical trials studying new and more effective ways to detect and treat cancer. Find clinical trials for advanced renal cell carcinoma.

May 10, 2023 · In this phase 3, double-blind trial, we enrolled patients with advanced clear-cell renal-cell carcinoma who had not previously received treatment and had intermediate or poor prognostic risk...

Oct 28, 2021 · Here’s what to know about current treatment options and new approaches being explored through clinical trials. Active surveillance for renal cell carcinoma. If renal cell carcinoma is growing slowly, active surveillance may be an option, says Pavlos Msaouel, M.D., Ph.D. Patients under active surveillance will have checkups every few months ...

Aug 21, 2024 · Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies. In a phase 3, multicenter, open-label,...

A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma Purpose. Researchers want to see how well a personalized vaccine works for people with kidney cancer when given with pembrolizumab immunotherapy.

Apr 17, 2024 · We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving patients who were disease-free on the basis of investigator assessment after surgery for clear-cell...

The Kidney Cancer Research Consortium brings together some of the nation’s best researchers in clinical kidney cancer trials, enabling multi-site studies at a greatly reduced cost. The collaborative nature of the Consortium also improves trial enrollment numbers and access to underserved populations of patients.